5 stories
Enforcement coverage on Peptide News Digest tracks the actual cases — DOJ indictments, FDA warning letters, state medical board actions, and MHRA and TGA orders against clinics, compounders, and individual prescribers.
Recent cases: the April 2026 federal indictment of a Utah osteopathic physician for selling 200+ patients misbranded Chinese peptides (semaglutide, tirzepatide, BPC-157, retatrutide); state medical board actions against peptide clinics; FDA warning letters to compounding pharmacies for sterile-compounding deficiencies; and the University of Colorado secret-shopper study quantifying how many medspas continued selling compounded GLP-1s after warning letters.
Stories here cover the indictments, the warning letters, and the policy moves that follow them. See #peptide-safety and #compounding for related threads.
A Utah physician was indicted for importing and selling misbranded drugs from China to over 200 patients. Customs separately seized 5,000 unapproved peptide units at the border.
The FDA published warning letters targeting companies marketing GLP-1 receptor agonists without regulatory approval, addressing CGMP violations and clinical trial protocol failures.
The FDA issued warning letters to 30 telehealth firms for false or misleading claims about compounded GLP-1 weight-loss products, signaling a major crackdown on illegal online marketing.
Healthcare Brew reports that despite the FDA sending thousands of warning letters since September 2025, compounded semaglutide and tirzepatide prescriptions have increased since the semaglutide shortage ended in February 2025. About 80% of compounded GLP-1 prescriptions now include supplemental ingredients like B vitamins to avoid being classified as exact copies of FDA-approved drugs.
PeptideSciences, one of the largest grey-market research peptide vendors in the US reportedly generating over $7 million per month, voluntarily ceased all operations on March 6. The shutdown followed coordinated enforcement from the FDA, DOJ, and FBI targeting companies selling compounds like semaglutide and tirzepatide without pharmaceutical licensing.